ArticleFrontiers in immunology2025

Benralizumab for adults with rare and off-label eosinophilic disorders: a 52-week prospective, single-center study.

Aviv Talmon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.